IL-15 and IFN-γ signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling

Despite effective new treatments for Hepatitis C virus (HCV) infection, development of drug resistance, safety concerns and cost are remaining challenges. More importantly, there is no vaccine available against hepatitis C infection. Recent data suggest that there is a strong correlation between spontaneous HCV clearance and human NK cell function, particularly IFN-gamma production. Further, IL-15 has innate antiviral activity and is also one of the main factors that activates NK cells to produce IFN-gamma. To examine whether IL-15 and IFN-gamma have direct antiviral activity against HCV, Huh7.5 cells were treated with either IFN-gamma or IL-15 prior to HCV infection. Our data demonstrate that IFN-gamma and IL-15 block HCV replication in vitro. Additionally, we show that IL-15 and IFN-gamma do not induce anti-HCV effects through the type I interferon signaling pathway or nitric oxide (NO) production. Instead, IL-15 and IFN-gamma provide protection against HCV via the ERK pathway. Treatment of Huh7.5 cells with a MEK/ERK inhibitor abrogated the anti-HCV effects of IL-15 and IFN-gamma and overexpression of ERK1 prevented HCV replication compared to control transfection. Our in vitro data support the hypothesis that early production of IL-15 and activation of NK cells in the liver lead to control of HCV replication.